LifeStance Health (LFST) Cash & Equivalents (2020 - 2026)

LifeStance Health (LFST) has 7 years of Cash & Equivalents data on file, last reported at $76.9 million in Q1 2026.

• Quarterly Cash & Equivalents fell 42.74% year-over-year to $76.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76.9 million (down 42.74% YoY) and the FY2025 annual result came in at $175.5 million, up 45.19% from the prior year.
• Cash & Equivalents eased to $76.9 million in Q1 2026 per LFST's latest filing, from $175.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $175.5 million in Q4 2025 and bottomed at $28.5 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $96.7 million (2022), against an average of $96.5 million.
• The widest annual swing landed in 2023, when Cash & Equivalents plunged 68.47%; it then jumped 314.62% in 2025.
• Tracing LFST's Cash & Equivalents over 5 years: stood at $108.6 million in 2022, then sank by 37.68% to $67.7 million in 2023, then surged by 78.57% to $120.9 million in 2024, then surged by 45.19% to $175.5 million in 2025, then tumbled by 56.17% to $76.9 million in 2026.
• Per Business Quant, the three latest LFST Cash & Equivalents figures stand at $76.9 million (Q1 2026), $175.5 million (Q4 2025), and $141.8 million (Q3 2025).

Peer Comparison